Merck & Co Inc MRK
News
Merck and Orion Announce Mutual Exercise of Option Providing Merck Global Exclusive Rights to Opevesostat, an Investigational CYP11A1 Inhibitor, for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Merck to Hold Second-Quarter 2024 Sales and Earnings Conference Call July 30
Merck Gets CHMP Backing of Winrevair in Pulmonary Arterial Hypertension
Merck Receives Positive EU CHMP Opinion for WINREVAIR™ (sotatercept) in Pulmonary Arterial Hypertension (PAH)
CDC’S ACIP Unanimously Recommends Merck’s CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Pneumococcal Vaccination in Appropriate Adults
FDA Turns Away Daiichi Sankyo, Merck Lung-Cancer ADC
Patritumab Deruxtecan BLA Submission Receives Complete Response Letter from FDA Due to Inspection Findings at Third-Party Manufacturer
Merck Animal Division's Dog Flu Treatment Gets Agriculture Department Approval
USDA Approves Merck Animal Health’s NOBIVAC® NXT Canine Flu H3N2 – The First and Only RNA-Particle Technology Vaccine for Canine Influenza
Germany's Merck Group shares drop 10% after scrapping trial of promising cancer drug
Merck on Track for Record High Close — Data Talk
Merck Is Partnering With America’s Largest HBCU To Launch a Collaborative Biotechnology Learning Center
Pancreatic Cancer Market Is Projecting to Expand As NCI-Funded Research Expects to Empower Market Growth
FDA Approves Merck's Vaccine For Adult Invasive Pneumococcal Disease
Merck Get FDA Approval for Keytruda to Treat Endometerial Cancer
U.S. FDA Approves CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Prevention of Invasive Pneumococcal Disease and Pneumococcal Pneumonia in Adults
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Carboplatin and Paclitaxel as Treatment for Adult Patients With Primary Advanced or Recurrent Endometrial Carcinoma
Merck's vaccine approval poses threat to one of Pfizer's top-selling products
Women in Science? At Merck, Absolutely